Objective. To evaluate the safety of and long-term pain relief due to intravenous lidocaine infusion for the treatment of chronic pain in a tertiary pain management clinic.
Introduction
Chronic noncancer pain in the United States is one of the most-cited reasons for which Americans access the health care system and is now a leading cause of social security disability [1] . Actual estimates of chronic pain prevalence are varied based on chronic pain definitions as well as study design; however, the National Institutes of Health reports that chronic pain affects more Americans than diabetes, heart disease, and cancer combined [2, 3] . As a consequence, chronic pain poses a huge economic burden, and the joint cost of pain-related US health care expenses and loss of productivity has been estimated to be between $560 and $635 billion dollars annually [4] . Unfortunately, despite the abundance of health care dollars invested in chronic pain treatment and research, many patients, particularly with various forms of neuropathic pain, have inadequate relief of their pain as a result of treatment with oral medications including opioids, surgery, and interventional therapies, and even interdisciplinary pain. In addition, opioid-related morbidity and mortality continue to plague our society, despite continued emphasis in recent guidelines (such as those of the Centers for Disease Control and Prevention [CDC] issued in spring 2016) on discouraging opioid use in treating chronic noncancer pain. According to the CDC, more than 165,000 people died from opioid pain medication overdose from 1999 to 2014. Frustratingly, at a time when the "chronic painopioid epidemic" has made national and international press, there are limited alternatives for the safe treatment of chronic pain, of which intravenous (i.v.) lidocaine infusions have shown promise.
Lidocaine is an amide local anesthetic that is widely used for regional anesthesia in surgery and in the treatment of acute postoperative pain [5, 6] . Lidocaine suppresses abnormal neuronal discharge by the blockade of sodium channels and N-methyl-D-aspartate receptors. Lidocaine also modulates or inhibits several other channels, including calcium, potassium, muscarinic, and glycinergic signaling, which could potentially lead to decreased spinal sensitization and reductions in spontaneous pain, hyperalgesia, and allodynia [7] . Intravenous lidocaine infusion was shown to be beneficial in the treatment of chronic pain, which is typically resistant to more traditional therapies [8, 9] . It showed short-term benefit for the treatment of a variety of neuropathic pain states (e.g., poststroke pain, peripheral neuropathy, diabetic neuropathy, and complex regional pain syndromes [CRPS] I and II) [10] .
To date, the longer-term efficacy of i.v. lidocaine infusions for chronic pain has been poorly studied, with available studies showing an overall fairly small benefit beyond placebo [10] [11] [12] [13] . Furthermore, previous studies involved small sample sizes and a variety of infusion protocols [14] [15] [16] [17] [18] . A recent retrospective chart review by Hutson et al. examined 69 patients with neuropathic pain receiving a total of 1,650 i.v. lidocaine infusions [19] . The authors note that patients experienced maximal pain relief at 24 hours postinfusion, though the degree of relief or the number of days of relief was not specifically delineated. Nevertheless, as 96% of the infusions analyzed were repeat visits, the results of the aforementioned study implied that lidocaine must have had continued efficacy for the population in question [19] . Currently, there is no consensus on optimal dosage, infusion rates, patient selection criteria, and outcomes of lidocaine infusion for chronic pain [10, 11, [19] [20] [21] .
The purpose of the current study is to document the duration of pain relief and patient tolerance for i.v. lidocaine infusions and determine if patients had sufficient pain relief and benefit duration to make repeat treatments desirable and feasible.
Methods
This retrospective chart review study was approved by the Institutional Review Board (IRB) at the University of Utah. Patient charts were included if individuals received their first i.v. lidocaine infusion for chronic pain at the University of Utah Pain Management Center (PMC) between July 2012 and July 2015. Patients were identified using search tools in collaboration with Business Technology Solutions at the University of Utah. Once the search identified patients who received lidocaine infusions at the PMC, the search extended to their initial new patient visit at the PMC and subsequent office visits and procedure visits.
Lidocaine Chart Review
Information for the chart reviews was extracted from the EPIC Electronic Medical Records program (Epic Systems Corp., Verona, WI, USA). A total of 233 patients and 469 separate visits for lidocaine infusion were identified and reviewed by either EI or KK, who did not provide clinical care for these patients. A subset of records (261 items) was reviewed by five PMC attending physicians specializing in pain medicine. Their assessments were compared with EI/KK in order to ensure inter-rater reliability.
Variables
Information of interest included basic demographic variables; pain assessment variables including duration, location, and diagnoses at the initial visit; and specific diagnosis for lidocaine infusion therapy. From the infusion records, we evaluated side effects and pre/post pain scores on the infusion days. Narrative notes at follow-up visits (typically four or more weeks) regarding the quality and duration of pain relief after the lidocaine infusion were also reviewed. Data were extracted from a maximum of three consecutive lidocaine visits for those patients who received multiple infusions.
Pain Relief
As part of the regular follow-up assessment, patients were asked to report on the presence of long-term benefits of infusions. For this study, it was agreed upon that lidocaine benefit be measured by documented improvement in pain, significant pain relief, amount of pain relief, and/or duration of reduced pain. Unclear notes or missing notes were documented as "unclear" and no return visit as "no follow-up." Where notes specified pain relief duration, prolonged benefit was agreed upon based on pain relief duration of seven or more days. If relief was noted for four to six days, it was coded as of unclear prolonged benefit, and relief of less than four days was coded as no prolonged benefit.
Pain Location and Diagnoses
Pain location was classified as generalized body, head/ face/neck, back (lower or upper), shoulders/arms/ hands, legs, chest/abdominal, and pelvic, anal, or genital. Pain diagnoses were categorized based on subtypes of neuropathic pain, such as chronic regional pain syndrome, postsurgical or post-traumatic, trigeminal neuralgia, cancer related, and other facial pain. Additional non-neuropathic categories included migraines/headaches, postsurgical or post-traumatic pain, radicular pain, myofascial pain, generalized pain, and other.
Lidocaine Infusion Procedures
The standard procedure of intravenous lidocaine infusions at the PMC uses an initial dose of 1,000 mg/h administered intravenously for up to 30 minutes. Patients are continuously monitored by a nurse every three to five minutes to check specifically for vital signs (BP, HR, and RR), patient pain levels, and reports of side effects. The infusion is continued until any of the following criteria is met: 1) patient pain has been fully resolved; 2) patient has completed the 30-minute infusion; 3) patient reports an acute intolerable or concerning side effect such as dizziness, nausea, or vomiting; or 4) patient wishes to stop. Patients receive a follow-up phone call 24 to 72 hours after the infusion to ascertain acute treatment benefits, presence of prolonged side effects, and patient concerns. The total dose administered during the first treatment is used for subsequent infusions over a 30-minute period. Patients are offered a four-week follow-up office visit to discuss treatment success, additional i.v. lidocaine, and future treatment plans.
Inter-rater Agreement
EI and KK conducted all 469 lidocaine visit chart reviews. Inter-rater reliability was determined by comparing a subset of records of 261 visits between EI/KK and those completed by the PMC attending physicians for the outcome of treatment benefit at the follow-up visit. The agreement was 72.80%, with a Kappa statistic of 0.54 (SE ¼ 0.044, P < 0.0001). Disagreements were primarily due to higher coding of patients as "unclear" by EI and KK based on the available notes, while attending physicians coded fewer patients as "unclear." This may be due to physician information from their personal interactions with the patients that may not have been included in the notes. The remainder of the manuscript will report results focused on the 469 records (233 patients) reviewed by EI and KK.
Statistical Analyses
Basic t tests and chi-square statistics were used for continuous and categorical variables, respectively. We examined potential associations between demographic and clinical variables and benefit from the initial lidocaine infusion using univariate logistic regressions. Covariates included gender, BMI, and age.
Results

Patient Demographics
A total of 233 patients were included in this study. Table 1 describes patient demographics and clinical diagnosis from the most proximal visit to the infusion and diagnosis category for which the infusion was targeted. Patients were an average age of 51 years (SD ¼ 15.0 years), 54% were female, there was an average BMI of 29 (SD ¼ 7.3), and patients had average pain duration of 7.7 years (SD ¼ 9.5 years). The pain diagnoses for patients who received lidocaine infusions are shown in Table 1 and consisted of 80% with neuropathic and 20% with non-neuropathic pain. Of the 233 patients, 142 received a second infusion and 94 received a third infusion. Patients who received more than one infusion (224 records) had an average of 33 days (SD ¼ 12.7 days) between infusions, with an additional 12 records having 100 days or more between infusions.
Treatment Doses and Side Effects
As discussed in the Methods section, per protocol guidelines, the first lidocaine infusion is 1000mg/h for 30 minutes (infusion rate of 16.67 mg/min). Notably, the first infusion is a challenge dose to determine the level of lidocaine that the patient can tolerate until complete pain relief, report of side effects, or completion of infusion. For the first infusion, the average total mg of lidocaine delivered was 381.4 mg (SD ¼ 120.9 mg), with a total infusion time of 23.0 minutes (SD ¼ 7.24 minutes). A histogram of the delivered amounts of lidocaine at the first infusion is shown in Figure 1 . Seventy-five percent of patients received 290mg or more with 40% of patients receiving the maximum of 500 mg. Of the 233 patients receiving their first lidocaine infusion, 53% reported no side effects and 46% reported mild side effects. One percent of records were missing information on side effects. Table 2 displays the types and proportion of side effects (SEs). The majority of SEs were minor and transient, resolving within minutes after the infusion was stopped. The most common SEs were perioral numbness (9.9%), dizziness (7.7%), tinnitus (5.6%), nausea (4.3%), and peripheral numbness/dysesthesias (3%). In addition, there were a few reports of cognitive/ emotional effects, chest tightness, hypo-or hypertension, and slurred speech. Other rare SEs included a sense of being suffocated (N ¼ 1) and involuntary shaking (N ¼ 3). There were no serious adverse events.
Subsequent infusions for all patients used the same dose as the one tolerated on the first infusion, but over 30 minutes. As expected, patients who experienced side effects had a decreased total dose at the first infusion (306 mg, SE ¼ 10.08 mg) compared with those without side effects (449.3 mg, SE ¼ 7.95 mg, P < 0.001) (Figure 2 ). These dose differences persisted as marginally significant trends at the second infusion, of 345.11 mg vs 394.08 mg (P ¼ 0.07), and the third infusion, of 340.25 mg vs 404.8 mg (P ¼ 0.10). There was no significant difference in total dose between males and females at the first infusion (376.7 mg females vs 387.16 mg males, P ¼ 0.51). Overall, there was a decrease in the percentage of patients experiencing side effects from the first (47%), to the second (13%), to the third infusion (10%). Those who experienced side effects on the first infusion were more likely to experience side effects on the second infusion (25.4% vs 4%, P < 0.001). Total mg of lidocaine Figure 1 The distribution of total mg of lidocaine delivered intravenously at the first lidocaine infusion (N ¼ 233). All patients received an infusion rate of 1,000 mg/h for a target of 30 minutes. Infusions were stopped when 1) pain fully resolved; 2) was completed; 3) patient reported acute intolerable or concerning side effects such as dizziness, nausea, or vomiting; or 4) patient wished to stop. 
Pain Reduction and Treatment Benefit
On the day of the first lidocaine infusion, the average numerical pain score was 5.67 (SE ¼ 0.10) before infusion and 2.38 (SE ¼ 0.11) immediately following the infusion (P < 0.001). As described in the Methods section, patients showing clinically meaningful benefit at the follow-up visits (scheduled at four-week intervals between infusions) were categorized as "benefit," "no benefit," "unclear," or "no follow-up." Where notes on the duration of relief were available, the benchmark was at least seven days. There were a total of 233 patients who received an initial lidocaine infusion, with 142 patients and 94 patients who underwent second and third infusions, respectively. Of the 233 patients who received an initial infusion, 41% were categorized as having benefitted, 40% as no benefit, 9% as unclear, and 10% as no follow-up visit. Of the 142 patients who received a second infusion, 51% had meaningful benefit, 34% no prolonged benefit, 8% unclear, and 7% no follow-up visit. Finally, of the 94 patients who received a third infusion, records reported that 60% had meaningful benefit, 25% no prolonged benefit, 9% unclear, and 7% no follow-up visit.
In order to ascertain if the response to lidocaine on the first visit is associated with the likelihood of receiving subsequent infusions and achieving pain relief, we separated the patients into those categorized as no benefit and benefit based on their response to the initial infusion. Figure 3 displays the number of patients who displayed benefit, no benefit, unclear, or no follow-up visit at the second and third infusions based on treatment response at the first infusion. Patients who benefitted on the first infusion were more likely to return for a second infusion compared with those who did not benefit after the first infusion (92% vs 36%, P < 0.001). Of the patients who received a second infusion, 63% benefitted at the second infusion, having also benefitted after the first infusion, compared with only 24% benefiting at the second infusion, having not benefitted at the first infusion (P < 0.001). Patients were also more likely to undergo a third infusion if they had a beneficial response at the second infusion compared with those who did not benefit after the second infusion (76.1% vs 41.2%, P < 0.001). Similarly, patients were more likely to benefit at the third infusion if they had a positive benefit from the second infusion (74.6%), compared with no benefit after the second infusion (21.4%, P < 0.001).
Duration of Benefit
Finally, we examined the reported pain relief duration following the first infusion based on clinical notes. Of the 233 patients who received an initial infusion, medical records from 98 patients included information on the duration of pain relief. Pain relief duration was categorized based on a range of relief (for example, report of less than one week, one to two weeks, two to three weeks, and three or more weeks). Of note, for the purposes of this study, less than one week of relief was categorized as no long-term benefit. Using this grouping for the records with duration information, after the first infusion, 40% of patients had less than one week of relief, 36% had one to two weeks, 16% had two to three weeks, and 8% had three or more weeks of relief.
Dose and Demographic and Clinical Factors Associated with Pain Relief (Seven or More Days) Following Initial Infusion
The logistic regression revealed no relationships between benefit of first lidocaine infusion and demographic data (sex, age, BMI) or patient's prior pain duration (all P > 0.20). Furthermore, there was no significant relationship between infusion dosage and probability of benefit after the initial infusion when controlling for demographic data (P > 0.9). Table 3 displays the frequency and proportions of patients who showed benefit based on pain diagnosis. Response to the initial infusion ranged between 32% and 58% within those diagnostic groups that contained more than 10 patients. There were no significant differences in the proportions of patients showing benefit based on clinical diagnosis.
Discussion
The results of the present study in 233 patients with chronic pain treated at a tertiary pain clinic suggest that i.v. lidocaine is safe. Only mild side effects were reported, and these side effects did not persist for more than a few None Side effects Figure 2 The relationship between total lidocaine dose (mg) and presence of side effects after the initial infusion. The challenge dose is 1,000 mg/h and is continued up to 500 mg, as described in the Methods section. N¼3 missing notes on SE.
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hours. Prolonged pain relief was reported in 41% of patients receiving an initial infusion. In many cases, pain relief lasted several weeks postinfusion for those classified as treatment responders. Patients who experienced treatment benefit after the first infusion were more likely to return and benefit from subsequent infusions. Of note, patient return may be influenced by many factors not assessed in this study, including medical insurance restrictions, inconvenience of securing a designated driver, distance to pain management center, and patient-provider decisions to pursue alternative therapies. We found that i.v. lidocaine was beneficial in neuropathic as well as non-neuropathic pain, including generalized pain, migraine/headaches, and myofascial pain (Table 3) . Treatment benefit was not associated with age, sex, BMI, pain diagnosis, or prior pain duration. Our preliminary data suggest positive benefit for diverse pain patients, thus supporting further efforts to identify the clinical factors associated with the likelihood of treatment response, including pain diagnosis, outcome measures, dosing frequency of infusions, and study of potential biological mechanisms.
Safety and Side Effects
The safety and tolerability of i.v. lidocaine are well established, but higher-dose lidocaine infusions are not without side effects [9, 10, 22] . The current study found that 47% of patients experienced side effects with the first infusion.
The majority of these were mild and subsided within minutes to hours postinfusion. This rate of side effects is lower than that described in Hutson et al. (80%) for similar infusion rates [19] . Importantly, as the first infusion is a challenge dose with expected side effects that informs infusion rates for subsequent infusions, side effects decreased dramatically with the second and third infusions. Forty-four percent of the patients in our sample continued at the same infusion rate at their second infusion, while the remainder decreased the rate based on the side effects and/or having achieved full pain relief before the infusion was complete. Interestingly, those who had side effects were less likely to experience positive benefit from the infusions. For some patients, undesirable side effects may be a deterrent from an otherwise beneficial therapy. The relationship between side effects, clinical benefit, and doctor-patient decisions for further infusions needs to be better delineated.
Prolonged Pain Relief
The current retrospective study is the largest study to date that examines the long-term benefit of individual lidocaine infusions in a heterogeneous chronic pain population. Our data suggest that 41% of patients who received an initial lidocaine infusion reported clinically meaningful pain relief and, where information was available, average prolonged pain relief of more than two weeks for treatment responders. Importantly, given that the initial lidocaine infusion is a Of those who were unclear, six benefitted at the second infusion and five at the third infusion. We omit the unclear group for simplicity. challenge dose, no or unclear prolonged benefit after the first infusion does not preclude benefit in subsequent infusions after changes in dosing and infusion rates have been made (see Figure 3) .
These results provide support that i.v. lidocaine infusions can yield prolonged pain relief in an otherwise treatment-refractory chronic pain population. Previous reports of prolonged benefit of lidocaine for pain have been mixed. There have been several studies that examined if there are benefits lasting longer than a few days after single infusions [10, 11, 14, 17, 18, 23, 24] . In these studies, estimation of how long pain relief persists after lidocaine infusion is difficult due to small sample sizes and variable dosing schemes. Several studies have also examined benefits following serial or continuous infusions, with reported benefits persisting for months. These include patients with chronic headaches from medication overuse [25] , CRPS [26] , and fibromyalgia [27, 28] . For a comprehensive Cochrane review on the use of lidocaine in neuropathic pain, including longterm relief, see Challapalli et al. [13] . Future studies should work to optimize treatment efficacy.
Benefits of i.v. Lidocaine Infusions for Diverse Pain Populations
In the current study cohort, intravenous lidocaine displayed prolonged pain relief of an average of one to two weeks in a diverse set of neuropathic and nonneuropathic pain conditions. Still, as this is a retrospective study, caution should be exercised in drawing any diagnosis-specific recommendations at this time, and several considerations must be noted. The current patient cohort had an average pain duration of 7.74 years, and patients may have had multiple pain problems with diverse etiologies and underlying mechanisms. In addition to variable disease presentation, patients may be undergoing any number of concurrent treatments that can contribute to pain relief, including changes or adjustment in medications, physical therapy, other procedures such as trigger point injections and nerve blocks, and and behavioral therapy approaches, which makes ascertaining the specific benefit of lidocaine infusions difficult. Therefore, it is important to carefully document all potential contributors to pain relief. In addition, there is a need for information capture pertaining not only to pain The "unclear" category is for patients who had a follow-up visit but whose narrative notes precluded conclusions in regard to clinical benefit. The "no follow-up" category is for those patients who did not attend a follow-up visit at the pain management clinic. The last column shows the percentage of patients benefitting after the first infusion, with those patients who were unclear or had no follow-up counted as having had no benefit. CRPS ¼ chronic regional pain syndrome; FMS ¼ fibromyalgia; n.o.s. ¼ not otherwise specified. *The "other" category includes individuals with Ehlers Danlos syndrome, Decrum's disease, bilateral flank pain, Crohn's disease, sarcoidosis and burning mouth syndrome, central pain syndrome, and interstitial cystitis.
severity, but also changes to pain location and quality. For example, research suggests that the benefit of acute lidocaine may be related to how patients label their pain experience. Carrol et al. (2010) found that neuropathic pain patients who describe their pain as "heavy" reported greater pain reduction during the infusion compared with those who described their pain as "stabbing" [29] .
The results from this study also support the need for frequent patient-reported outcomes as well as medications and concurrent treatments for days and weeks following the infusion. At the clinic, standard of care is for patients to be scheduled to return four weeks following infusions. However, of those patients with information on the duration of pain relief, 40% had less than a week's benefit, 35% had one to two weeks, and the remainder two or more weeks. Therefore, if relief lasts an average of one to two weeks, the patient may be best served by having infusions more frequently than every four weeks. Because of the increased availability of cell phone applications and telemedicine, it becomes feasible to obtain frequent daily log recordings in the patient's natural environment. Home assessment of daily or more frequent symptom monitoring has been successfully used with many chronic pain conditions [31] [32] [33] [34] . Therefore, frequent assessment of changes in pain-related outcomes could help patients and doctors determine the duration and extent of pain relief following lidocaine infusions. Finally, because patients are often selected based on treatment refractory pain, they may be susceptible to prolonged placebo effects due to expectancy of benefit (30) . Future research studies should consider placebo-controlled frameworks to determine the extent of placebo response and if it wanes over time with repeated infusions. Information on prolonged relief from a relatively safe and repeatable treatment could further clarify the costeffectiveness and utility of lidocaine infusions in managing pain and other associated symptoms.
Strengths and Limitations
The current study is the largest to date examining the prolonged (more than seven days) benefits of i.v. lidocaine infusions for patients with chronic pain. Though retrospective and descriptive in nature, it nevertheless provides preliminary information on the side effects and treatment benefit for a diverse group of chronic pain patients. However, as often occurs in retrospective chart reviews, charting was not complete in some cases, leading to missing data. Results could only be obtained from the available resources at the initial and follow-up visits; thus the determination of pain relief duration following the infusion is rather crude. Furthermore, as noted above, patients often have concurrent treatments that can potentially complicate a patient's ability to ascribe pain relief specifically to lidocaine infusions. Future prospective studies should address these concerns by more thorough assessments of pain relief duration, changes in pain severity and quality, and rigorously recording additional therapies and alterations in medications that may contribute to pain relief.
Conclusion
The current retrospective chart review of 233 patients with chronic pain treated with i.v. lidocaine demonstrates that the therapy was administered safely and without serious adverse event, with reported minor side effects being less common on subsequent infusions. Additionally, in this treatment refractory pain population, 41% of patients reported clinically meaningful prolonged pain relief after a single treatment. Of patients noting benefit after the initial infusion, 94% returned for a second infusion, with 60% showing continued benefit. Finally, although the majority of the patient population was diagnosed as having neuropathic pain, non-neuropathic groups also displayed prolonged benefit, suggesting that lidocaine may be beneficial for a range of chronic pain diagnoses. Future studies are necessary to explore the relationships between lidocaine infusion dosage, treatment frequency, benefit duration, and treatment cost-effectiveness.
